Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows:
- sale of drugs (98.9%): for the treatment of HIV (50% of net sales), COVID-19 (7.4%), hepatitis C virus (4%), hepatitis B virus (1.4%) and other (37.2%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV);
- other (1.3%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products.
Net sales are distributed geographically as follows: the United States (70.6%), Europe (17.8%) and other (11.6%).
Number of employees : 14 400 people.
2020 2021 Delta Innovative Medicines 24 689.00 100% 27 305.00 100% +10.6%
USD in Million
2020 2021 Delta United States 18 217.00 73.8% 19 267.00 70.6% +5.76%
Europe 4 135.00 16.7% 4 874.00 17.9% +17.87%
Other International 2 337.00 9.5% 3 164.00 11.6% +35.39%
USD in Million
Vote Quantity Free-Float Company-owned shares Total Float
Stock A
1
1,254,313,448
1,253,513,224
99.9%
0
0.0%
99.9%
Shareholders Gilead Sciences, Inc. (US) Gilead Sciences, Inc. (BRGILDBDR000)
Name Equities % The Vanguard Group, Inc. 100,472,614
8.00% Capital Research & Management Co. 64,780,000
5.16% SSgA Funds Management, Inc. 57,970,959
4.62% Capital Research & Management Co. (Global Investors) 55,951,379
4.46% Capital Research & Management Co. (World Investors) 49,501,852
3.94% Dodge & Cox 37,026,630
2.95% BlackRock Fund Advisors 28,319,140
2.26% Geode Capital Management LLC 22,703,667
1.81% Arrowstreet Capital LP 18,002,214
1.43% Renaissance Technologies LLC 15,492,116
1.23%
Name Equities % Caixa DTVM SA 52,165
0.0021% Bram Bradesco Asset Management S/A DTVM 12,080
0.0005% BB Gestão de Recursos DTVM SA 10,586
0.0004%
Name Equities % Valuation
GALAPAGOS NV (GLPG)
16,707,477
25.5%
987,030,960 USD
ARCUS BIOSCIENCES, INC. (RCUS)
13,913,029
19.4%
336,834,432 USD
SIERRA ONCOLOGY, INC. (SRRA)
725,283
3.03%
39,535,176 USD
TANGO THERAPEUTICS, INC. (TNGX)
4,852,550
5.53%
35,714,768 USD
JOUNCE THERAPEUTICS, INC. (JNCE)
5,539,727
10.7%
29,360,553 USD
AGENUS INC. (AGEN)
11,111,111
4.32%
20,555,555 USD
ALLOGENE THERAPEUTICS, INC. (ALLO)
1,156,689
0.81%
9,658,353 USD
HOOKIPA PHARMA INC. (HOOK)
3,759,465
7.39%
5,639,198 USD
- Nasdaq Global Select Market
- Nasdaq 100 / S&P 100, S&P 500, Stoxx Global 200
- Bloomberg Code :
GILD:US
- Reuters Code :
GILD.O
- Datastream Code :
Company contact information
Gilead Sciences, Inc.
333 Lakeside Drive
CA 94404 San Mateo, California
Phone : +1 650 574 3000
Fax : +1 650 578 9264
web site :
http://www.gilead.com
GSK to buy Sierra Oncology amid pressure to boost drug pipeline
Sector Bio Therapeutic Drugs
1st jan. Capi. (M$)
GILEAD SCIENCES, INC. -10.47% 81 543
REGENERON PHARMACEUTICALS, INC. 9.40% 74 440
VERTEX PHARMACEUTICALS 23.33% 69 269
WUXI APPTEC CO., LTD. -25.70% 39 423
BIONTECH SE -40.00% 37 588
GENMAB A/S -19.73% 19 850
ARGENX SE -6.82% 17 140
BEIGENE, LTD. -52.97% 13 146
NEUROCRINE BIOSCIENCES, INC. 3.77% 8 447
HALOZYME THERAPEUTICS, INC. 11.46% 6 378
LEGEND BIOTECH CORPORATION -15.98% 6 040
SAREPTA THERAPEUTICS, INC. -23.94% 5 993
EXELIXIS, INC. -2.57% 5 712
INTRA-CELLULAR THERAPIES, INC. 8.27% 5 345
ASCENDIS PHARMA A/S -32.88% 5 039
BIOCON LIMITED -11.09% 4 972
MARAVAI LIFESCIENCES HOLDINGS, INC. -18.35% 4 500
CEREVEL THERAPEUTICS HOLDINGS, INC. -17.00% 3 990
ARROWHEAD PHARMACEUTICALS, INC. -48.76% 3 592
PHARMAESSENTIA CORPORATION 17.58% 3 394
CYTOKINETICS, INCORPORATED -14.98% 3 319
Connections : Gilead Sciences, Inc.